<DOC>
	<DOC>NCT01517607</DOC>
	<brief_summary>This non-interventional study examines whether the patient's level of information and the consideration of the patient's preference have a positive effect on the compliance and thus also on the therapeutic success.</brief_summary>
	<brief_title>Mesalazine (PENTASA®) in Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients are treated for the first time with oral PENTASA®, e.g. following first diagnosis of ulcerative colitis for treatment of an acute episode or Following a therapyfree period (no previous mesalazine therapy) or due to poor response or underdosage oder lacking acceptance of the previous medication the patients are readjusted to oral PENTASA®, The patients (≥ 18 years) have been informed about the NIS and have given their written consent for participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>